← Leaderboards
Mary E. Klotman
Mount Sinai School Of Medicine Of Cuny
$14,207,269
Attributed
$16,183,146
Total exposure
15
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,802,771 · 17
By mechanism
P01$21,268,475 · 9
R01$6,204,227 · 3
R21$1,377,025 · 3
T32$953,044 · 1
U19$0 · 1
Top collaborators
- John C He4 shared
- Kyung W Lee4 shared
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroCellsIn VivoHiv InfectionsReportingHiv-1ProteinsBiopsyPreventGenetic TranscriptionIntegraseVirusEpithelial CellsImmune ResponseResponseLeadSiteViralAntigensKidneyMediatingHiv VaccineMouse ModelHuman Immunodeficiency Virus 1
Grant awards (66)
The role of Vpr-mediated cell cycle dysregulation in HIV-associated kidney disease$733,538
R01 · FY2025 · DK
The role of Vpr-mediated cell cycle dysregulation in HIV-associated kidney disease$710,734
R01 · FY2024 · DK
The role of Vpr-mediated cell cycle dysregulation in HIV-associated kidney disease$740,348
R01 · FY2023 · DK
The role of Vpr-mediated cell cycle dysregulation in HIV-associated kidney disease$779,195
R01 · FY2022 · DK
Persistent HIV Infection in the Kidney(Duke)$386,929
P01 · FY2021 · DK · contact PI
Persistent HIV Infection in the Kidney(Duke)$348,014
P01 · FY2020 · DK · contact PI
Integrase Defective Lentiviral Vector (IDLV)-ENV Immunogen Strategy for an HIV Vaccine$1,526,960
P01 · FY2019 · AI · contact PI
Safety and Durability of Integrase Defective Lentiviral vector for an HIV Vaccine$524,547
P01 · FY2019 · AI · contact PI
The Genitourinary Tract as a compartment and reservoir for HIV$481,822
R01 · FY2019 · DK · contact PI
Persistent HIV Infection in the Kidney(Duke)$347,099
P01 · FY2019 · DK · contact PI
Administrative Core$141,507
P01 · FY2019 · AI · contact PI
Integrase Defective Lentiviral Vector (IDLV)-ENV Immunogen Strategy for an HIV Vaccine$1,831,862
P01 · FY2018 · AI · contact PI
Safety and Durability of Integrase Defective Lentiviral vector for an HIV Vaccine$515,543
P01 · FY2018 · AI · contact PI
The Genitourinary Tract as a compartment and reservoir for HIV$481,822
R01 · FY2018 · DK · contact PI
Persistent HIV Infection in the Kidney(Duke)$365,541
P01 · FY2018 · DK · contact PI
Administrative Core$134,005
P01 · FY2018 · AI · contact PI
Integrase Defective Lentiviral Vector (IDLV)-ENV Immunogen Strategy for an HIV Vaccine$1,924,538
P01 · FY2017 · AI · contact PI
Safety and Durability of Integrase Defective Lentiviral vector for an HIV Vaccine$615,983
P01 · FY2017 · AI · contact PI
The Genitourinary Tract as a compartment and reservoir for HIV$481,823
R01 · FY2017 · DK · contact PI
Administrative Core$149,707
P01 · FY2017 · AI · contact PI
Persistent HIV Infection in the Kidney(Duke)$89,737
P01 · FY2017 · DK · contact PI
Integrase Defective Lentiviral Vector (IDLV)-ENV Immunogen Strategy for an HIV Vaccine$1,858,150
P01 · FY2016 · AI · contact PI
Safety and Durability of Integrase Defective Lentiviral vector for an HIV Vaccine$508,783
P01 · FY2016 · AI · contact PI
The Genitourinary Tract as a compartment and reservoir for HIV$481,823
R01 · FY2016 · DK · contact PI
Administrative Core$124,663
P01 · FY2016 · AI · contact PI
Integrase Defective Lentiviral Vector (IDLV)-ENV Immunogen Strategy for an HIV Vaccine$1,848,708
P01 · FY2015 · AI · contact PI
Safety and Durability of Integrase Defective Lentiviral vector for an HIV Vaccine$491,191
P01 · FY2015 · AI · contact PI
The Genitourinary Tract as a compartment and reservoir for HIV$481,823
R01 · FY2015 · DK · contact PI
Administrative Core$134,635
P01 · FY2015 · AI · contact PI
Prothymosin-Alpha- A Novel Antiviral Restriction Factor$211,875
R21 · FY2009 · AI · contact PI
HIV Integrase as a Target for Topical MIcrobicide Development$211,875
R21 · FY2009 · AI · contact PI
HIV Integrase as a Target for Topical MIcrobicide Development$30,102
R21 · FY2009 · AI · contact PI
VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHY$279,133
P01 · FY2008 · DK · contact PI
Prothymosin-Alpha- A Novel Antiviral Restriction Factor$254,250
R21 · FY2008 · AI · contact PI
HIV Integrase as a Target for Topical MIcrobicide Development$254,248
R21 · FY2008 · AI · contact PI
Physician Scientist Research Training in Pathogenesis of Viral Diseases$48,946
T32 · FY2008 · AI · contact PI
VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHY$339,253
P01 · FY2007 · DK · contact PI
Physician Scientist Research Training in Pathogenesis of Viral Diseases$134,195
T32 · FY2007 · AI · contact PI
VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHY$337,417
P01 · FY2006 · DK · contact PI
Non-Integrating Lentiviral Vectors: Potential as Vaccines$198,650
R21 · FY2006 · AI · contact PI
Physician Scientist Research Training in Pathogenesis of Viral Diseases$128,594
T32 · FY2006 · AI · contact PI
VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHY$327,589
P01 · FY2005 · DK
Non-Integrating Lentiviral Vectors: Potential as Vaccines$216,025
R21 · FY2005 · AI
Dimandelic Acid Ethers As Topical Microbicides For HIV$1,190,534
P01 · FY2004 · HD
VIRAL PATHOGENESIS OF HIV ASSOCIATED NEPHROPATHY$318,048
P01 · FY2004 · DK
PHYS SCI RES TRAINING IN PATHOGENESIS OF VIRAL DISEASES$138,642
T32 · FY2004 · AI
Dimandelic Acid Ethers As Topical Microbicides For HIV$1,159,341
P01 · FY2003 · HD
PHYS SCI RES TRAINING IN PATHOGENESIS OF VIRAL DISEASES$138,078
T32 · FY2003 · AI
Dimandelic Acid Ethers As Topical Microbicides For HIV$1,129,055
P01 · FY2002 · HD
HIV1 INHIBITORY PROTEINS FROM TRANSFORMED CD8+ CELLS$273,614
R01 · FY2002 · AI
CORE--CLINICAL AND MOUSE CORE$228,547
P01 · FY2002 · DK
PHYS SCI RES TRAINING IN PATHOGENESIS OF VIRAL DISEASES$128,885
T32 · FY2002 · AI
Optimization of Microbicide Combinations Against HIV-1$0
U19 · FY2002 · HD
Mechanism of inhibition of HIV by dimandelic acid ethers$0
P01 · FY2002 · HD
Dimandelic Acid Ethers As Topical Microbicides For HIV$1,150,477
P01 · FY2001 · HD
HIV1 INHIBITORY PROTEINS FROM TRANSFORMED CD8+ CELLS$265,645
R01 · FY2001 · AI
CORE--CLINICAL AND MOUSE CORE$228,547
P01 · FY2001 · DK
EVALUATION OF DELIVERY SYSTEMS FOR RENAL GENE THERAPY$196,218
P01 · FY2001 · DK
PHYS SCI RES TRAINING IN PATHOGENESIS OF VIRAL DISEASES$123,371
T32 · FY2001 · AI
Mechanism of inhibition of HIV by dimandelic acid ethers$0
P01 · FY2001 · HD
HIV1 INHIBITORY PROTEINS FROM TRANSFORMED CD8+ CELLS$292,040
R01 · FY2000 · AI
CORE--CLINICAL AND MOUSE CORE$287,667
P01 · FY2000 · DK
CORE--CLINICAL AND MOUSE CORE$228,547
P01 · FY2000 · DK
PHYS SCI RES TRAINING IN PATHOGENESIS OF VIRAL DISEASES$112,333
T32 · FY2000 · AI
EVALUATION OF DELIVERY SYSTEMS FOR RENAL GENE THERAPY$0
P01 · FY2000 · DK
EVALUATION OF DELIVERY SYSTEMS FOR RENAL GENE THERAPY$0
P01 · FY2000 · DK